We are attempting to secure research funds to develop a new formulation for nasal vaccines. This formulation will facilitate antigen delivery to immune cells by temporarily disrupting nasal epithelial permeability barriers. We envisage utilizing our new formulation to develop a nasal vaccine against tuberculosis. Such a vaccine would be particularly useful in countering the entrance of tubercle bacilli into the human body by inhalation and subsequent establishment of lung infections.
Other Funding Source:
We have yet to secure funding for this project.